AGC Biologics has successfully manufactured more than 200 biological projects for pre-clinical studies through commercial approvals. Our global facilities span three continents and offer multiple cGMP manufacturing lines at a variety of scales for mammalian cell culture and microbial fermentation.
We develop and manufacture diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. We also develop and manufacture adeno-associated viral vectors, lenti viral vectors and retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house.
"Asia's largest partnering event consisting of Exhibition, Seminar, and Partnering program" This event is consituted by three exhibitions - 1. The world's oldest biotechnology exhibition "BioJapan" (1986-), 2. "Regenerative Medicine JAPAN" (2016-), aiming to accelerate and industrialize R&D in the field of regenerative medicine including iPS cells, and 3."health TECH JAPAN"(2020-), provides fusion of digital technology and life science. We are focusing on providing new value by business partnering of industry, academia, and government which is not limited to Japan, but also from overseas. With the addition of Digital & In-Person partnering program started from 2020, global innovation through this partnering event never stop at all.